[54] Souto JC, Martinez E, Roca M, Mateo J, Pujol J, Gonzalez D, Fontcuberta J.

Prothrombotic state and signs of endothelial lesion in plasma of patients with

inflammatory bowel disease. Dig Dis Sci 1995;40:1883-1889.

[55] Collins CE, Cahill MR, Newland AC, Rampton DS. Platelets circulate in an activated

state in inflammatory bowel disease. Gastroenterology 1994;106:840-845.

[56] Dhillon AP, Anthony A, Sim R, Wakefield AJ, Sankey EA, Hudson M, Allison MC,

Pounder RE. Mucosal capillary thrombi in rectal biopsies. Histopathology

1992;21:127-133.

[57] Wakefield AJ, Sawyerr AM, Dhillon AP, Pittilo RM, Rowles PM, Lewis AA, Pounder

RE. Pathogenesis of Crohn's disease: multifocal gastrointestinal infarction. Lancet

1989;2:1057-1062.

[58] Van Deventer SJ. Tumor necrosis factor and Crohn’s disease. Gut 1997;40: 443-448.

[59] Nassif A, Longo WE, Mazuski JE, Vernava AM, Kaminski DL. Role of cytokines and

platelet-activating factor in inflammatory bowel disease. Implications for therapy. Dis

Colon Rectum 1996;39:217–223.

[60] Bevilacqua MP, Pober JS, Majeau GR, Fiers W, Cotran RS, Gimbrone MA Jr.

Recombinant tumor necrosis factor induces procoagulant activity in cultured human

vascular endothelium: characterization and comparison with the actions of interleukin

1. Proc Natl Acad Sci USA 1986;83:4533–4537.

[61] Nawroth PP, Stern DM. Modulation of endothelial cell hemostatic properties by tumor

necrosis factor. J Exp Med 1986;163:740–745.

[62] Dosquet C, Weill D, Wautier JL. Cytokines and thrombosis. J Cardiovasc Pharmacol

1995;25 (Suppl 2): S13-19.

[63] Aadland E, Odegaard OR, Roseth A, Try K. Free protein S deficiency in patients with

chronic inflammatory bowel disease. Scand J Gastroenterol 1992;27:957-960.

[64] Aadland E, Odegaard OR, Roseth A, Try K. Free protein S deficiency in patients with

Crohn’s disease. Scand J Gastroenterol 1994;29:333-335.

[65] Heneghan MA, Cleary B, Murray M, O’Gorman TA, McCatrhy CF. Activated protein

C resistance, thrombophilia, and inflammatory bowel disease. Dig Dis Sci

1998;43:1356-1361.

76 Petros Zezos and Georgios Kouklakis

[66] Gallagher PM, Meleady R, Shields DC, Tan KS, McMaster D, Rozen R, Evans A,

Graham IM, Whitehead AS. Homocysteine and risk of premature coronary disease:

Evidence for a common gene mutation. Circulation 1996;94:2154 -2158.

[67] Ridker PM, Hennekens CH, Selhub J, Miletich JP, Malinow MR, Stampfer MJ.

Interrelation of hyperhomocyst(e)inemia, factor V Leiden, and risk of future venous

thromboembolism. Circulation 1997;95:1777-1782.

[68] Cantu C, Alonso E, Jara A, Martinez L, Rios C, Fernandez Mde L, Garcia I,

Barinagarrementeria F. Hyperhomocysteinemia, low folate and vitamin B12

concentrations, and methylene tetrahydrofolate reductase mutation in cerebral venous

thrombosis. Stroke 2004;35:1790-1794.

[69] den Heijer M, Koster T, Blom HJ, Bos GM, Briet E, Reitsma PH, Vandenbroucke JP,

Rosendaal FR. Hyperhomocysteinemia as a risk factor for deep-vein thrombosis. N

Engl J Med 1996;334:759-762.

[70] Ray JG. Meta-analysis of hyperhomocysteinemia as a risk factor for venous

thromboembolic disease. Arch Intern Med 1998;158:2101-2106.

[71] Langman LJ, Ray JG, Evrovski J, Yeo E, Cole DE. Hyperhomocyst(e)inemia and the

increased risk of venous thromboembolism: more evidence from a case-control study.

Arch Intern Med 2000;160:961-964.

[72] McCully KS. Homocysteine and vascular disease. Nat Med 1996;2:386-389.

[73] Seshadri N, Robinson K. Homocysteine, B vitamins and coronary artery disease. Med

Clin North Am 2000;84:215-237.

[74] Welch GN, Loscalzo J. Homocysteine and atherothrombosis. N Engl J Med

1998;338:1042-1050.

[75] McCully KS. Homocysteine, folate, vitamin B6, and cardiovascular disease. JAMA

1998;279:392-393.

[76] Loscalzo J. The oxidant stress of hyperhomocyst(e)inemia. J Clin Invest 1996;98:5-7.

[77] Mahmud N, Molloy A, McPartlin J, Corbally R, Whitehead AS, Scott JM, Weir DG.

Increased prevalence of methylenetetrahydrofolate reductase C677T variant in patients

with inflammatory bowel disease, and its clinical implications. Gut 1999;45:389-394.

[78] Oldenburg B, Fijnheer R, van der Griend R, vanBerge-Henegouwen GP,

Koningsberger JC. Homocysteine in inflammatory bowel disease: a risk factor for

thromboembolic complications? Am J Gastroenterol 2000;95:2825-2830.

[79] Romagnuolo J, Fedorak RN, Dias VC, Bamforth F, Teltscher M.

Hyperhomocysteinemia and inflammatory bowel disease: prevalence and predictors in

a cross-sectional study. Am J Gastroenterol 2001;96:2143-2149.

[80] Papa A, De Stefano V, Danese S, Chiusolo P, Persichilli S, Casorelli I, Zappacosta B,

Giardina B, Gasbarrini A, Leone G, Gasbarrini G. Hyperhomocysteinemia and

prevalence of polymorphisms of homocysteine metabolism-related enzymes in patients

with inflammatory bowel disease. Am J Gastroenterol 2001;96:2677-2682.

[81] Drzewoski J, Gasiorowska A, Malecka-Panas E, Bald E, Czupryniak L. Plasma total

homocysteine in the active stage of ulcerative colitis. J Gastroenterol Hepatol

2006;21:739-743.

[82] Gonera RK, Timmerhuis TP, Leyten AC, van der Heul C. Two thrombotic

complications in a patient with active ulcerative colitis. Neth J Med 1997;50:88-91.

Nutritional Issues in Inflammatory Bowel Disease… 77

[83] Slot WB, van Kasteel V, Coerkamp EG, Seelen PJ, van der Werf SD. Severe

thrombotic complications in a postpartum patient with active Crohn's disease resulting

in ischemic spinal cord injury. Dig Dis Sci 1995;40:1395-1399.

[84] Elikowski W, Malek M, Lewandowska M, Kawczynski S, Dobrowolska-Zachwieja

A,Psuja P. Massive pulmonary embolism in a patient with ulcerative colitis and

hyperhomocysteinaemia -- a case report. Kardiol Pol 2006;64:405-409.

[85] Younes-Mheni S, Younes-Mhenni S, Derex L, Berruyer M, Nighoghossian N,

Philippeau F, Salzmann M, Trouillas P. Large-artery stroke in a young patient with

Crohn's disease. Role of vitamin B6 deficiency-induced hyperhomocysteinemia. J

Neurol Sci 2004;221:113-115.

[86] Kao A, Dlugos D, Hunter JV, Mamula P, Thorarensen O. Anticoagulation therapy in

cerebral sinovenous thrombosis and ulcerative colitis in children. J Child Neurol

2002;17:479-482.

[87] Papa A, Santoliquido A, Danese S, Covino M, Di Campli C, Urgesi R, Grillo A,

Guglielmo S, Tondi P, Guidi L, De Vitis I, Fedeli G, Gasbarrini G, Gasbarrini A.

Increased carotid intima-media thickness in patients with inflammatory bowel disease.

Aliment Pharmacol Ther 2005;22:839-846.

[88] Morgenstern I, Raijmakers MT, Peters WH, Hoensch H, Kirch W. Homocysteine,

cysteine, and glutathione in human colonic mucosa: elevated levels of homocysteine in

patients with inflammatory bowel disease. Dig Dis Sci 2003;48:2083-2090.

[89] Danese S, Sgambato A, Papa A, Scaldaferri F, Pola R, Sans M, Lovecchio M,

Gasbarrini G, Cittadini A, Gasbarrini A. Homocysteine triggers mucosal microvascular

activation in inflammatory bowel disease. Am J Gastroenterol 2005;100:886-895.

[90] Burrin DG, Stoll B. Emerging aspects of gut sulfur amino acid metabolism. Curr Opin

Clin Nutr Metab Care 2007;10:63-68.

[91] Choi SW, Mason JB. Folate status: effects on pathways of colorectal carcinogenesis. J

Nutr 2002;132:2413S-2418S.

[92] Kim YI. Folate and carcinogenesis: evidence, mechanisms, and implications. J Nutr

Biochem 1999;10:66-88.

[93] Bailey LB, Rampersaud GC, Kauwell GP. Folic acid supplements and fortification

affect the risk for neural tube defects, vascular disease and cancer: evolving science. J

Nutr 2003;133:1961S-1968S.

[94] Giovannucci E. Epidemiologic studies of folate and colorectal neoplasia: a review. J

Nutr 2002;132:2350S-2355S.

[95] Potter JD. Methyl supply, methyl metabolizing enzymes and colorectal neoplasia. J

Nutr 2002;132:2410S-2412S.

[96] Eaden JA, Mayberry JF. Colorectal cancer complicating ulcerative colitis: a review. Am

J Gastroenterol 2000;95:2710-2719.

[97] Eaden JA, Abrams KR, Mayberry JF. The risk of colorectal cancer in ulcerative colitis:

a meta-analysis. Gut 200;48:526-535.

[98] Lashner BA, Silverstein MD, Hanauer SB. Hazard rates for dysplasia and cancer in

ulcerative colitis. Results from a surveillance program. Dig Dis Sci 1989;34:1536-1541.

78 Petros Zezos and Georgios Kouklakis

[99] Greenstein AJ, Sachar DB, Smith H, Pucillo A, Papatestas AE, Kreel I, Geller SA,

Janowitz HD, Aufses AH Jr. Cancer in universal and left-sided ulcerative colitis:

factors determining risk. Gastroenterology 1979;77:290-294.

[100] Eaden J. Review article: colorectal carcinoma and inflammatory bowel disease. Aliment

Pharmacol Ther 2004;20 (Suppl 4):24-30.

[101] Meyer F, White E. Alcohol and nutrients in relation to colon cancer in middle-aged

adults. Am J Epidemiol 1993;138:225–36.

[102] Benito E, Stiggelbout A, Bosch FX, Obrador A, Kaldor J, Mulet M, Munoz N.

Nutritional factors in colorectal cancer risk: a case-control study in Majorca. Int J

Cancer 1991;49:161-167.

[103] Freudenheim J, Graham S, Marshall J, Haughey B, Cholewinski S, Wilkinson G. Folate

intake and carcinogenesis of the colon and rectum. Int J Epidemiol 1991; 20: 368–74.

[104] Lashner BA, Heidenreich PA, Su GL, Kane SV, Hanauer SB. Effect of folate

supplementation on the incidence of dysplasia and cancer in chronic ulcerative colitis.

A case-control study. Gastroenterology 1989;97:255–259.

[105] Lashner BA. Red blood cell folate is associated with the development of dysplasia and

cancer in ulcerative colitis. J Cancer Res Clin Oncol 1993;119:549 –554.

[106] Lashner BA, Provencher KS, Seidner DL, Knesebeck A, Brzezinski A. The effect of

folic acid supplementation on the risk for cancer or dysplasia in ulcerative colitis.

Gastroenterology 1997;112:29 –32.

[107] Carrier J, Medline A, Sohn KJ, Choi M, Martin R, Hwang SW, Kim YI. Effects of

dietary folate on ulcerative colitis-associated colorectal carcinogenesis in the

interleukin 2- and beta(2)-microglobulin-deficient mice. Cancer Epidemiol Biomarkers

Prev 2003;12:1262-1267.

[108] Simpson SJ, Mizoguchi E, Allen D, Bhan AK, Terhorst C. Evidence that CD4+, but not

CD8+ T cells are responsible for murine interleukin-2-deficient colitis. Eur J Immunol

1995;25:2618-2625.

[109] Shah SA, Simpson SJ, Brown LF, Comiskey M, de Jong YP, Allen D, Terhorst C.

Development of colonic adenocarcinomas in a mouse model of ulcerative colitis.

Inflamm Bowel Dis 1998;4:196-202.

[110] Sohn KJ, Shah SA, Reid S, Choi M, Carrier J, Comiskey M, Terhorst C, Kim YI.

Molecular genetics of ulcerative colitis-associated colon cancer in the interleukin 2-

and beta(2)-microglobulin-deficient mouse. Cancer Res 2001;61:6912-6917.

[111] Ryan BM, Weir DG. Relevance of folate metabolism in the pathogenesis of colorectal

cancer. J Lab Clin Med 2001;138:164-76.

[112] Kim YI. Folate, colorectal carcinogenesis, and DNA methylation. Lessons from animal

studies. Environ Mol Mutagen 2004;44:10-25.

[113] Kim YI. Role of folate in colon cancer development and progression. J Nutr

2003;133:3731S-3739S..

[114] Kim YI. Nutritional epigenetics: impact of folate deficiency on DNA methylation and

colon cancer susceptibility. J Nutr 2005;135:2703–2709.

[115] Duthie SJ, Narayanan S, Sharp L, Little J, Basten G, Powers H. Folate, DNA stability

and colo-rectal neoplasia. Proc Nutr Soc 2004;63:571-578.

Nutritional Issues in Inflammatory Bowel Disease… 79

[116] McNulty H, McKinley MC, Wilson B, McPartlin J, Strain JJ, Weir DG, Scott JM.

Impaired functioning of thermolabile methylenetetrahydrofolate reductase is dependent

on riboflavin status: implications for riboflavin requirements. Am J Clin Nutr

2002;76:436-441.

[117] Hustad S, Ueland P, Vollset S, Zhang Y, Bjorke-Monsen A, Schneede J. Riboflavin as

a determinant of plasma total homocysteine: effect modification by the

methylenetetrahydrofolate reductase C677T polymorphism. Clin Chem 2000;46:1065-

1071.

[118] Bernstein CN, Blanchard JF, Kliewer E, Wajda A. Cancer risk in patients with

inflammatory bowel disease: a population-based study. Cancer 2001;91:854-862.

[119] Maykel JA, Hagerman G, Mellgren AF, Li SY, Alavi K, Baxter NN, Madoff RD.

Crohn's colitis: the incidence of dysplasia and adenocarcinoma in surgical patients. Dis

Colon Rectum 2006;49:950-957.

[120] Jess T, Gamborg M, Matzen P, Munkholm P, Sorensen TI. Increased risk of intestinal

cancer in Crohn's disease: a meta-analysis of population-based cohort studies. Am J

Gastroenterol 2005;100:2724-2729.

[121] Siegel CA, Sands BE. Risk factors for colorectal cancer in Crohn's colitis: a casecontrol study. Inflamm Bowel Dis 2006;12:491-496.

[122] Friedman S, Rubin PH, Bodian C, Goldstein E, Harpaz N, Present DH. Screening and

surveillance colonoscopy in chronic Crohn's colitis. Gastroenterology 2001;120:820-

826.

[123] Greenstein AJ. Cancer in inflammatory bowel disease. Mt Sinai J Med 2000;67:227-

240.

 

4. Management of Vitamin B Complex Deficiencies in IBD Patients and

Recommendations

Nutrition support should be considered as an important element of a multidimensional

management of all IBD patients. Although no specific recommendations exist, clinicians

involved in the management of patients with inflammatory bowel disease should regularly

assess the diet and the nutritional status of these patients. Every effort should be made to

always maintain these patients in a well-balanced diet that is rich in nutrients.

Usually, the nutritional needs can be met by food alone together or not with a

multivitamin supplement. Nutritional support as adjunctive therapy should be employed in

any malnourished patient, in those with complications due to specific nutrient deficiencies

and in those who have difficulty in maintaining a normal nutritional status. Special nutritional

considerations are required for specific groups of patients including children, adolescents,

candidates for surgery and those with: severe active disease, severe disease complications

(fistulas, stenoses), and extensive bowel resection with or without short bowel syndrome.

In regard to the “vitamin B complex”, the major concern is to identify and treat the

vitamin B6, vitamin B12 and folate deficiencies, since they are associated with severe

complications in IBD patients (anemia, thrombosis and colon cancer). The other “vitamin B

complex” members’ deficiencies observed in some studies did not have any specific clinical

impact, although some clinical syndromes due to their deficiency have been rarely described.

Nutritional Issues in Inflammatory Bowel Disease… 71

Multivitamin supplements contain adequate amounts for daily requirements of watersoluble B vitamins, and can be used for the prophylaxis against deficiencies of these

micronutrients.

Treatment of macrocytic anemia in IBD patients does not differ from the general

population (intramuscular injections of hydroxycobalamin in vitamin B12 deficiency or

folinic acid orally in folate deficiency).

Hyperhomocysteinemia may be present in IBD patients and has been associated with

thromboembolic complications. Cattaneo et al. [131] found that hyperhomocysteinemia in

IBD patients could be corrected by the administration of folate, vitamin B12 and vitamin B6.

Many other studies assessing the homocysteine and “vitamin B complex” status in IBD

patients suggested the daily administration of folate, vitamin B12 and vitamin B6 for

prophylaxis against hyperhomocysteinemia and thrombotic complications [17,21,39], since

studies have shown a lowering effect on serum homocysteine levels by daily administration

of “vitamin B complex” supplements [132-135]. It is hoped that lowering homocysteine

towards normal serum levels would reduce the risk for thrombosis, but a recent study, the

VITRO trial [135], showed that homocysteine lowering by “vitamin B complex”

supplementation did not prevent recurrent venous thrombosis.

Finally, previous studies have linked folate deficiency with increased cancer risk in UC

patients [104-106]. Evidence from small clinical studies suggests that folate supplementation

in UC patients may have a protective effect against colorectal cancer since it has been

associated with a dose-dependent reduced risk [106] or with an improvement of surrogate

markers of colorectal cancer (DNA repair defects or rectal cell hyperproliferation) [136,137].

However, folate supplementation for colorectal neoplasia chemoprevention should be

regarded with great caution. Animal studies have shown that the protective effect of folate is

dose and timing related, since folate supplementation reduces the risk of colorectal cancer in

normal colorectal mucosa, whereas folate supplementation has a promoting effect on the

progression of established microscopic neoplasmatic foci in the colorectal mucosa and

colorectal neoplasms [138]. Large prospective studies are needed to clarify the

chemopreventive role of folate against colorectal cancer in ulcerative colitis.

CONCLUSION

• Nutrition-related issues are important components of the global assessment in the

management of patients with inflammatory bowel disease.

• Several nutrient deficiencies, including the “vitamin B complex” members, are

frequently observed in IBD patients. The aetiology of nutrient deficiencies is

multifactorial and clinicians should be aware of the malnutrition existence and its

clinical consequences in IBD patients.

• Nutritional status and nutrient intake should be regularly assessed in all IBD patients.

Children, adolescents, perioperative patients, patients with severe disease or

complications and patients with extended small bowel resection, need special

attention.

72 Petros Zezos and Georgios Kouklakis

• Any specific nutrient deficiency should be corrected together with diet adjustment

and prophylactic polyvitamin supplementation when appropriate.

• “Vitamin B complex” supplements protect against macrocytic anemia,

hyperhomocysteinemia and their complications in IBD patients.

• Folate supplementation may have a protective role against colorectal cancer in IBD

patients.

REFERENCES

[1] Sartor RB. Current concepts of the etiology and pathogenesis of ulcerative colitis and

Crohn’s disease. Gastroenterol Clin North Am 1995;24:475-505.

[2] Fiocchi C. Inflammatory bowel disease: etiology and pathogenesis. Gastroenterology

1998;115:182-205.

[3] Geerling BJ, Stockbrugger RW, Brummer RJ. Nutrition and inflammatory bowel

disease: an update. Scand J Gastroenterol Suppl 1999;230:95-105.

[4] Reif S, Klein I, Lubin F, Farbstein M, Hallak A, Gilat T. Pre-illness dietary factors in

inflammatory bowel disease. Gut 1997;40:754-760.

[5] Geerling BJ, Dagnelie PC, Badart-Smook A, Russel MG, Stockbrugger RW, Brummer

RJ. Diet as a risk factor for the development of ulcerative colitis. Am J Gastroenterol

2000;95:1008-1013.

[6] Zurita VF, Rawls DE, Dyck WP. Nutritional support in inflammatory bowel disease.

Dig Dis 1995;13:92-107.

[7] Seidman EG. Nutritional management of inflammatory bowel disease. Gastroenterol

Clin North Am 1989;18:129-155.

[8] Dieleman LA, Heizer WD. Nutritional issues in inflammatory bowel disease.

Gastroenterol Clin North Am 1998;27:435-451.

[9] Han PD, Burke A, Baldassano RN, Rombeau JL, Lichtenstein GR. Nutrition and

inflammatory bowel disease. Gastroenterol Clin North Am 1999;28:423-443.

[10] Graham TO, Kandil HM. Nutritional factors in inflammatory bowel disease.

Gastroenterol Clin North Am. 2002 ;31(1):203-218.

[11] Fernandez-Banares F, Abad-Lacruz A, Xiol X, Gine JJ, Dolz C, Cabre E, Esteve M,

Gonzalez-Huix F, Gassull MA. Vitamin status in patients with inflammatory bowel

disease. Am J Gastroenterol 1989;84:744-748.

[12] Kuroki F, Iida M, Tominaga M, Matsumoto T, Hirakawa K, Sugiyama S, Fujishima M.

Multiple vitamin status in Crohn's disease. Correlation with disease activity. Dig Dis

Sci 1993;38:1614-8.

[13] Geerling BJ, Badart-Smook A, Stockbrugger RW, Brummer RJ. Comprehensive

nutritional status in recently diagnosed patients with inflammatory bowel disease

compared with population controls. Eur J Clin Nutr 2000;54:514-521.

[14] Filippi J, Al-Jaouni R, Wiroth JB, Hebuterne X, Schneider SM. Nutritional deficiencies

in patients with Crohn's disease in remission. Inflamm Bowel Di. 2006;12:185-191.

Nutritional Issues in Inflammatory Bowel Disease… 73

[15] Geerling BJ, Badart-Smook A, Stockbrugger RW, Brummer RJ. Comprehensive

nutritional status in patients with long-standing Crohn disease currently in remission.

Am J Clin Nutr 1998;67:919-926.

[16] Magee EA, Edmond LM, Tasker SM, Kong SC, Curno R, Cummings JH. Associations

between diet and disease activity in ulcerative colitis patients using a novel method of

data analysis. Nutr J 2005;4:7.

[17] Saibeni S, Cattaneo M, Vecchi M, Zighetti ML, Lecchi A, Lombardi R, Meucci G,

Spina L, de Franchis R. Low vitamin B(6) plasma levels, a risk factor for thrombosis,

in inflammatory bowel disease: role of inflammation and correlation with acute phase

reactants. Am J Gastroenterol 2003;98:112-117.

[18] Wolters M, Strohle A, Hahn A. Cobalamin: a critical vitamin in the elderly. Prev Med

2004;39:1256-1266.

[19] Chowers Y, Sela BA, Holland R, Fidder H, Simoni FB, Bar-Meir S. Increased levels of

homocysteine in patients with Crohn's disease are related to folate levels. Am J

Gastroenterol 2000;95:3498-3502.

[20] Lambert D, Benhayoun S, Adjalla C, Gelot MA, Renkes P, Felden F, Gerard P,

Belleville F, Gaucher P, Gueant JL, Nicolas JP. Crohn's disease and vitamin B12

metabolism. Dig Dis Sci 1996;41:1417-1422.

[21] Koutroubakis IE, Dilaveraki E, Vlachonikolis IG, Vardas E, Vrentzos G, Ganotakis E,

Mouzas IA, Gravanis A, Emmanouel D, Kouroumalis EA. Hyperhomocysteinemia in

Greek patients with inflammatory bowel disease. Dig Dis Sci 2000;45:2347-2351.

[22] Vasilopoulos S, Saiean K, Emmons J, Berger WL, Abu-Hajir M, Seetharam B, Binion

DG. Terminal ileum resection is associated with higher plasma homocysteine levels in

Crohn's disease. J Clin Gastroenterol 2001;33:132-136.

[23] Thompson WG, Wrathell E. The relation between ileal resection and vitamin B12

absorption. Can J Surg 1977;20:461-464.

[24] Lenz K. The effect of the site of lesion and extent of resection on duodenal bile acid

concentration and vitamin B12 absorption in Crohn's disease. Scand J Gastroenterol

1975;10:241-248.

[25] Behrend C, Jeppesen PB, Mortensen PB. Vitamin B12 absorption after ileorectal

anastomosis for Crohn's disease: effect of ileal resection and time span after surgery.

Eur J Gastroenterol Hepatol 1995;7:397-400.

[26] Duerksen DR, Fallows G, Bernstein CN. Vitamin B12 malabsorption in patients with

limited ileal resection. Nutrition 2006;22:1210-1213.

[27] Ooi BC, Barnes GL, Tauro GP. Normalization of vitamin B12 absorption after ileal

resection in children. J Paediatr Child Health 1992;28:168-171.

[28] Nilsson LO, Myrvold HE, Swolin B, Ojerskog B. Vitamin B12 in plasma in patients

with continent ileostomy and long observation time. Scand J Gastroenterol

1984;19:369-374.

[29] M'Koma AE, Lindquist K, Liljeqvist L. Biochemical laboratory data in patients before

and after restorative proctocolectomy. A study on 83 patients with a follow-up of 36

months. Ann Chir 1994;48:525-534.

[30] Elsborg L. Vitamin B12 and folic acid in Crohn's disease. Dan Med Bull 1982;29:362-

365.

74 Petros Zezos and Georgios Kouklakis

[31] Kennedy HJ, Callender ST, Truelove SC, Warner GT. Haematological aspects of life

with an ileostomy. Br J Haematol 1982;52:445-454.

[32] Jayaprakash A, Creed T, Stewart L, Colton B, Mountford R, Standen G, Probert C.

Should we monitor vitamin B12 levels in patients who have had end-ileostomy for

inflammatory bowel disease? Int J Colorectal Dis 200419:316-318.

[33] Christl SU, Scheppach W. Metabolic consequences of total colectomy. Scand J

Gastroenterol Suppl 1997;222:20-24.

[34] Bayat M, Brynskov J, Dige Petersen H, et al. Direct and quantitative vitamin B12

absorption measurement in patients with disorders in the distal part of the bowel.

Comparison of stool spot test [SST] with whole body counting in patients with ileal

pelvic reservoir, ileostomy or Crohn’s disease. Int J Colorectal Dis 1994;9:68–72.

[35] M’Koma AE. Follow-up results of hematology data before and after restorative

proctocolectomy. Clinical outcome. Dis Colon Rectum 1994;37:932–937.

[36] M'koma AE. Serum biochemical evaluation of patients with functional pouches ten to

20 years after restorative proctocolectomy. Int J Colorectal Dis 2006;2:711-720.

[37] Kuisma J, Nuutinen H, Luukkonen P, Jarvinen H, Kahri A, Farkkila M. Long term

metabolic consequences of ileal pouch-anal anastomosis for ulcerative colitis. Am J

Gastroenterol 2001;96:3110-3116.

[38] Steger GG, Mader RM, Vogelsang H, Schofl R, Lochs H, Ferenci P. Folate absorption

in Crohn's disease. Digestion 1994;55:234-238.

[39] Zezos P, Papaioannou G, Nikolaidis N, Vasiliadis T, Giouleme O, Evgenidis N.

Hyperhomocysteinemia in ulcerative colitis is related to folate levels. World J

Gastroenterol 2005;11:6038-6042.

[40] Hodges P, Gee M, Grace M, Thomson AB. Vitamin and iron intake in patients with

Crohn's disease. J Am Diet Assoc 1984;84:52-58.

[41] Bambach CP, Hill GL. Long term nutritional effects of extensive resection of the small

intestine. Aust N Z J Surg 1982;52:500-506.

[42] Elsborg L, Larsen L. Folate deficiency in chronic inflammatory bowel diseases. Scand

J Gastroenterol 1979;14:1019-1024.

[43] Hoffbrand AV, Stewart JS, Booth CC, Mollin DL. Folate deficiency in Crohn's disease:

incidence, pathogenesis, and treatment. Br Med J 1968;2:71-75.

[44] Lakatos L, Pandur T, David G, Balogh Z, Kuronya P, Tollas A, Lakatos PL.

Association of extraintestinal manifestations of inflammatory bowel disease in a

province of western Hungary with disease phenotype: results of a 25-year follow-up

study. World J Gastroenterol 2003;9:2300-2307.

[45] Glade MJ. Workshop on Folate, B12, and Choline. Sponsored by the Panel on Folate

and other B vitamins of the Standing Committee on the Scientific Evaluation of Dietary

Reference Intakes, Food and Nutrition Board, Institute of Medicine, Washington, D.C.,

March 3-4, 1997. Nutrition 1999;15:92-96.

[46] Alpers DH. What is new in vitamin B(12)? Curr Opin Gastroenterol 2005;21:183-186.

[47] British Committee for Standards in Haematology. Guidelines on the investigation and

diagnosis of cobalamin and folate deficiency. Clin Lab Haematol 1994;16:101–115.

[48] Portoles J, Romero JR, Gallego E, Llamas F, Sanchez-Tarraga L. Red cell folate: an

appropriate index of folate body stores. Nephron 1997;76:119.

Nutritional Issues in Inflammatory Bowel Disease… 75

[49] Galloway M, Rushworth L. Red cell or serum folate? Results from the National

Pathology Alliance benchmarking review. J Clin Pathol 2003;56:924-926.

[50] Talbot RW, Heppell J, Dozois RR, Beart RW Jr. Vascular complications of

inflammatory bowel disease. Mayo Clin Proc 1986;61:140-145.

[51] Vecchi M, Cattaneo M, de Francis R, Mannucci PM. Risk of thromboembolic

complications in patients with inflammatory bowel disease. Study of hemostasis

measurements. Int J Clin Lab Res 1991;21:165-170.

[52] Graef V, Baggenstoss AH, Sauer WG. Venous thrombosis occurring in non-specific

ulcerative colitis. Arch Intern Med 1965;117:377-382.

[53] Hudson M, Hutton RA, Wakefield AJ, Sawyerr AM, Pounder RE. Evidence for

activation of coagulation in Crohn’s disease. Blood Coagul Fibrinolysis 1992;3:773-

778.

 

Folate deficiency has often been described both in Crohn’s disease and ulcerative colitis

(Table 1). Decreased dietary intake, increased demands, malabsorption due to mucosal

impairment and sulfasalazine competitive inhibition of folate absorption, are associated with

folate deficiency. Folate deficiency may also be primary or secondary to vitamin B12

deficiency. Besides systemic deficiency, increased intestinal cell turnover due to epithelial

inflammation could also result in folate deficiency in patients with UC. Steger et al.

performed an oral folate absorption test in 100 CD patients and detected abnormal folate

absorption in 25 patients. The abnormal folate absorption test was correlated with disease

extent and activity. Furthermore, no increase of the serum folate levels was detected in 9 out

of 25 patients after oral folate supplementation [38]. Koutroubakis et al. reported that serum

folate levels were significantly lower in both CD and UC patients than in controls [21]. Zezos

et al. investigated the folate, vitamin B12 and homocysteine status in 40 UC patients and

identified 3 (7.5%) cases with low serum folate levels [39]. High prevalence (20-80%) of

folate deficiency in IBD patients is reported in data from 70’s and 80’s [11,40-43]. On the

contrary, in recent studies the prevalence of folate deficiency was low or even absent in IBD

patients, although serum folate levels were lower in IBD patients compared to healthy

controls [19,21,22]. One possible explanation for this discrepancy on data is the modification

of dietary folate intake in the recent years in the general population or the more frequent use

of vitamin supplements, including IBD patients. Furthermore, nowadays sulfasalazine has

been replaced by mesalazine, a drug that does not interfere with folate absorption, although a

correlation between intake of sulfasalazine and low folate levels has not been constantly

found in IBD patients [12,42]

64 Petros Zezos and Georgios Kouklakis

3. Clinical Consequences of Vitamin B Complex Deficiencies in IBD

Patients

The “vitamin B complex” deficiencies are implicated in a wide array of clinical

manifestations or complications in patients with IBD. Macrocytic anemia is associated with

folate and vitamin B12 deficiency. Deficiencies of folate, vitamin B12 and vitamin B6 can

cause hyperhomocysteinemia, an independent risk factor for both venous and arterial

thrombosis. Furthermore, low folate status has been associated with increased risk of

adenoma or colorectal cancer development in the general population and in individuals with

ulcerative colitis. Finally, there have been some rare cases reporting clinical syndromes

related to specific deficiencies of water-soluble B vitamins (pellagra, beriberi).

Megaloblastic Anemia in IBD Patients

Iron deficiency and anemia of chronic disease are the most common causes of anemia in

IBD patients [44]. Megaloblastic anemia due to folate or vitamin B12 deficiency is a less

frequent cause of anemia in IBD patients. The vitamin B12 is stored in the liver (~5 mg) and

has a low turnover rate with small daily requirements. In patients with inflammatory bowel

disease, ileal disease disrupting the enterohepatic circulation leads t greater losses of vitamin

B12 than that of a vegetarian not ingesting any vitamin B12. Thus, vitamin B12 deficiency

would occur in these patients in only a few years. Clinical evidence of vitamin B12 deficiency

occurs late as body stores have to be depleted to less than 10%. Vitamin B12 deficiency seems

to be common in patients with ileal CD or resection of the ileum, but its haematopoietic

consequence in CD is unclear. In general, folate deficiency seems to be more common than

vitamin B12 deficiency. Clinical manifestations of folate deficiency occur earlier as folate

stores last only 1-2 months.

In a recent study, Lakatos et al. [44] reported that the prevalence of macrocytic anemia

was 4.3% in CD patients and 4.9% in UC patients, but unfortunately without distinguishing

between folate and vitamin B12 deficiency. Overall, the percentages of macrocytic anemia

among anemic IBD patients were 7.3% in CD patients and 9.2% in UC patients.

Although folate and vitamin B12 deficiencies occur often in IBD patients the

manifestations of symptomatic deficiency (hematological and neurological consequences),

are not usually present. Several studies have observed a discrepancy between the measured

serum concentration of vitamin B12 and true deficiency as confirmed by Schilling test and

methylmalonic acid concentration. Methylmalonic acid accumulates in vitamin B12

deficiency and is specific for vitamin B12 deficiency state [45,46]. One possible explanation is

that in malnutrition states the carrier proteins in the serum are depleted before tissue levels

fall enough to produce symptoms of deficiency, and therefore serum levels of vitamin B12 do

not reflect true body stores. In general, red blood cell folate levels are considered as a better

indicator of tissue stores (intermediate-term stores) than serum folate levels (short-term

stores), and are less susceptible to rapid changes in diet [47,48]. Since most of the studies

have evaluated the serum folate status in IBD patients, it is possible that the folate deficiency

reported is not severe enough (depletion of tissue stores) to produce clinically evident

macrocytic anemia. On the other hand, some investigators suggest that serum folate

Nutritional Issues in Inflammatory Bowel Disease… 65

measurements provide equivalent information to red cell folate measurements about folate

status [49].

Hyperhomocysteinemia and Thromboembolic Disease in IBD Patients

The risk for thromboembolic complications is increased in patients with inflammatory

bowel disease. The incidence of arterial and venous thromboembolic disease in patients with

ulcerative colitis and Crohn’s disease has been reported between 1% and 8% [50,51], rising

to an incidence of 39% in some autopsy studies [52]. Several studies have shown that a

hypercoagulable state involving all components of clotting system exists in IBD [53-55]. This

hypercoagulable state may be related to an increased tendency for thromboembolic events

and may be linked to the disease pathogenesis through promoting microthrombi formation in

the intestinal microcirculation [56,57]. The aetiology and pathogenesis of the

hypercoagulable state in IBD have not been fully elucidated but may be induced through a

procoagulant effect of proinflammatory cytokines [58-62] in combination with acquired or

genetic defects of clotting factors (protein S, protein C, antithrombin, factor V Leiden,

prothrombin mutation 20210A, antiphospholipid antibodies) [63-65].

Homocysteine (Hcys) is a non-essential, sulfur-containing amino acid formed during the

metabolism of methionine (Figure 1). The first step in the synthesis of homocysteine is the

formation of S-adenosylmethionine (SAM, AdoMet), an important methyl donor, from

methionine. AdoMet is then converted to S-adenosylhomocysteine (AdoHcy), which is

further hydrolyzed to yield homocysteine and adenosine. Depending on whether there is a

relative excess or a deficiency of methionine, homocysteine may then enter either

transsulfuration or remethylation pathways. If methionine stores are adequate, homocysteine

enters the transsulfuration pathway, where it is converted to cysteine in a series of reactions

catalyzed by the vitamin B6 -dependent enzymes cystathionine beta-synthase (CBS) and

gamma-cystathionase. If methionine conservation is necessary, homocysteine enters a

remethylation pathway. Remethylation may occur by one of two reactions. In one,

homocysteine is reconverted to methionine by transfer of a methyl group from 5-

methyltetrahydrofolate in a reaction catalyzed by cobalamin (vitamin B12)-dependent

methionine synthase (MS). The formation of 5-methyltetrahydrofolate is catalyzed by

methylenetetrahydrofolate reductase (MTHFR), which requires vitamin B2 (riboflavin) as a

cofactor. The other remethylation pathway operates independently of vitamin B12 and folate

but uses betaine as a methyl donor and requires betaine-homocysteine methyltransferase

(BHMT). Abnormalities of these pathways, as a result of nutrient deficiencies or enzyme

inactivity, may result in the accumulation of homocysteine.

Mild hyperhomocysteinemia (hHcys), which occurs in approximately 5-7% of the

general population, has been proved to be thrombogenic and an independent risk factor for

coronary artery disease [66], arterial and venous thrombosis [67-72]. Elevated levels of Hcys

may result from abnormalities in metabolism pathways due to inherited abnormalities of the

enzymes involved or nutrient deficiencies such as insufficiency of folate and vitamins B2, B6

and B12 [73-74].

66 Petros Zezos and Georgios Kouklakis

Figure 1. Metabolic pathways of homocysteine.

The mechanism by which hyperhomocysteinemia promotes thrombosis is uncertain, but

it may be related to promoting a hypercoagulate state due to endothelial dysfunction [74-76].

Vitamin B12 and folate deficiency are relatively common conditions in IBD (especially in

active disease) through malnutrition, malabsorption or antifolate drugs such as methotrexate

and sulfasalazine. Deficiencies of key nutrients/cofactors in Hcys metabolism pathways (B2,

B6, B12, and folate) might lead to raised Hcys levels in IBD.

The association between IBD and hyperhomocysteinemia (hHcys) has been shown in

many recent studies, reporting an increased prevalence of hHcys in IBD (both UC and CD)

[17,19,21,22,39,77-81]. In most of these studies low serum folate level (and, to a lesser

extent, a low serum vitamin B12 level) was a strong independent risk factor for

hyperhomocysteinemia. Koutroubakis et al [21], Zezos et al. [39], Chowers et al. [19], and

Papa et al. [80] reported elevated homocysteine levels related to low serum folate status in

IBD patients. On the other hand, Romagnuolo et al. [79] reported an inverse correlation

between serum homocysteine levels and serum vitamin B12 levels. Furthermore, Saibeni et al.

[17] in their study underscored the relationship between low vitamin B6 plasma levels and

hyperhomocysteinemia in IBD patients. Moreover, Oldenburg et al. [78] found that

hyperhomocysteinemia correlated with serum folate, vitamin B12 and vitamin B6 status in

IBD patients. On the contrary, Drzewoski et al. [81] stated that elevated homocysteine levels

in UC patients correlated with disease activity and duration, and not with folate and vitamin

B12 deficiency.

Nutritional Issues in Inflammatory Bowel Disease… 67

Thromboembolic disease is a serious extraintestinal manifestation of inflammatory bowel

disease (IBD), causing significant morbidity and mortality in IBD patients. Thrombosis

occurs more often in the deep veins of the legs and the pulmonary circulation; however,

arterial thrombotic complications and numerous other less frequent sites of venous

thrombosis have also been described: cerebrovascular disease, internal carotid artery

occlusion, portal vein thrombosis, Budd-Chiari syndrome, cutaneous gangrene secondary to

microvascular thrombosis, retinal vein occlusion, ischaemic heart disease.

Hyperhomocysteinemia has been reported in the test results in cases of thromboembolic

complications in IBD patients. In our study [39], folate deficiency-related

hyperhomocysteinemia was found in one UC patient with severe cerebrovascular accident.

Gonera et al. reported cerebral venous thrombosis and deep vein thrombosis associated with

mild hyperhomocysteinemia in a 30-year-old woman with recently diagnosed ulcerative

colitis [82]. Slot et al. [83], described a case of folate deficiency-related

hyperhomocysteinemia in a 33-year-old woman with Crohn’s disease who presented with

ischemic spinal cord injury due to thrombosis of the distal aorta during a relapse of the

disease. Moreover, in another case [84] severe massive pulmonary embolism was described

in a young man with ulcerative colitis and laboratory investigation revealed

hyperhomocysteinemia due to folate and vitamin B12 deficiency. In addition, Younes-Mheni

et al. [85], reported a case of large-artery stroke in a 39-year-old woman with Crohn’s disease

due to vitamin B6 deficiency-induced hyperhomocysteinemia. Finally, Kao et al. [86]

described 4 pediatric patients with ulcerative colitis and cerebral sinovenous thrombosis.

Increased homocysteine levels were found in one patient.

Recently, Papa et al. [87] reported that elevated serum homocysteine was an important

factor associated with increased intima-media thickness of the wall of the common carotid

artery in IBD patients.

Increased homocysteine levels have also been observed in colonic mucosa of patients

with inflammatory bowel disease [88]. In a recent study, Danese et al. [89] observed

increased levels of homocysteine both in plasma and intestinal mucosa in IBD patients.

Increased levels of homocysteine contributed to mucosal microvascular inflammation through

activation of the endothelium.

Studies indicate that 20% of dietary methionine is metabolized in the gastrointestinal

tract. The gastrointestinal tract accounts for ~25% of whole body transmethylation and

transsulfuration and is a site of homocysteine release to the systemic circulation. It is possible

that a fraction of the increased circulating homocysteine levels in IBD patients may be due to

increased intestinal synthesis [90]. Further studies are needed to investigate the association

between the serum and mucosal homocysteine, the folate status and the inflammatory injury

in patients with inflammatory bowel disease.

Folate and Colorectal Carcinogenesis in IBD Patients

Research data from the past decade provided evidence that folate status may be involved

with the development and prevention of several malignancies, including cancer of the

colorectum, lungs, pancreas, esophagus, stomach, cervix, and breast, as well as

neuroblastoma and leukemia [91,92]. Overall, research data suggest an inverse association

68 Petros Zezos and Georgios Kouklakis

between folate status and the risk of these malignancies [91,92]. The role of folate in

carcinogenesis has been best studied for colorectal cancer [92-95].

Folate and Ulcerative Colitis-Associated Colorectal Carcinogenesis

Patients with chronic ulcerative colitis have a grater risk of developing colorectal cancer

than the general population [96]. In a recent meta-analysis of all published studies reporting

the colorectal cancer risk in ulcerative colitis patients, Eaden et al. reported that the risk for

any patient with ulcerative colitis is 2% at 10 years, 8% at 20 years, and 18% after 30 years

of disease [97]. Increased extent and longer duration of the disease are known risk factors for

the development of dysplasia and colorectal cancer in UC patients [98-100].

Epidemiological data have shown an inverse relationship between dietary folate intake

and sporadic colorectal cancer [101-103]. Although there is no direct evidence to link any

dietary factor and cancer risk, folate deficiency, which is common in UC patients, may be

implicated in the development of dysplasia and colorectal cancer in these patients. Lashner et

al. [104] first reported that individuals with long-standing ulcerative colitis and taking folate

supplementation had 62% lower incidence of colorectal dysplasia and cancer compared with

those not receiving folate supplementation. In another study by Lashner et al., the risk of

colorectal dysplasia and cancer was found to be significantly decreased by 18% for each 10

ng/ml increase in red blood cell folate concentrations in patients with ulcerative colitis [105].

Moreover, in a recent study, folic acid supplementation had an inverse dose-dependent

relationship with the risk of colorectal neoplasia in subjects with longstanding ulcerative

colitis [106]. These studies suggest an inverse relationship between folate status and the risk

of ulcerative colitis-associated colorectal cancer. There are currently no placebo-controlled

studies of folate supplementation in the prevention of ulcerative colitis-associated cancer.

Studies with animal models of colorectal dysplasia and cancer associated with ulcerative

colitis (interleukin-2 and β2- microglobulin deficient mouse) [107-110], have shown that

dietary folate supplementation at four times the basal dietary requirement significantly

suppresses colorectal carcinogenesis associated with ulcerative colitis in this model [107].

Carcinogenic Effects of Folate Deficiency

Folate is an essential cofactor for purine and pyrimidine metabolism and plays and

important role in DNA synthesis and cellular proliferation (Figure 2). Folate is also a critical

factor for DNA methylation (Figure 2), which is important epigenetic determinant in gene

expression, in the maintenance of DNA integrity and stability, in chromosomal modifications

and in the development of mutations. [91,92,111-115].

Accumulating evidence from in vitro, animal and human studies indicates that folate

deficiency is associated with DNA damage though many mechanisms (DNA strand breaks,

impaired DNA repair, altered DNA methylation and increased mutations) (Table 3), that

contribute to colorectal cancer development, and that folate supplementation can correct

some of these folate deficiency-induced defects [91,92,111-115].

Nutritional Issues in Inflammatory Bowel Disease… 69

Figure 2. Folate metabolic cycle involving DNA synthesis and methylation.

Table 3. Potential mechanisms of the folate deficiency-mediated colorectal cancer

development

1. Aberrant genomic and site specific DNA methylation

 Deactivation of tumor suppressor genes

2. Altered DNA methylation (hypomethylation) and cellular proliferation

 Increased gene expression

 DNA strand breaks, acquisition of mutations

 Proto-oncogene activation

3. DNA damage, nucleotide pool imbalance (uracil misincorporation)

4. Increased mutagenesis

5. Abnormal apoptosis

6. MTHFR polymorphisms ( thermolabile variant C677T) and related gene-nutrient

interactions

Impact of other Micronutrients in Colorectal Neoplasia

Some other members of the “vitamin B complex”, that participate in folate metabolism

play also role in DNA stability. The vitamin B12 is a cofactor for methionine synthase and

hence is a critical modulator of cellular methylation status. Riboflavin is also an important

cofactor for the MTHFR enzyme (Figure 2). Recently it has been demonstrated that

riboflavin binds with lower affinity to the MTHFR thermolabile variant (TT variant, C677T

mutation) and that riboflavin deficiency further impairs the functioning of this enzyme

[116,117]. Therefore, low riboflavin levels might accentuate the metabolic defect in MTHFR

thermolabile variant carriers, whereas high riboflavin levels might minimize the defect.

70 Petros Zezos and Georgios Kouklakis

The vitamin B12 and riboflavin levels were not measured in the majority of studies and

therefore their impact on the risk of developing colorectal cancer cannot be estimated. Future

studies in this area will have to address both the genetic and micronutrient factors (folate,

ideally colonic epithelial levels, vitamin B12, and methionine levels among others) involved

in folate metabolism to unravel the relative importance of each element.

A number of studies have suggested an increased risk of colorectal cancer in patients

with Crohn’s colitis [118,119,120], but few data exist about the factors that increase the risk

of dysplasia and colorectal cancer in Crohn’s colitis patients [121-125]. Although the risk of

colorectal neoplasia appears to be of the same magnitude in UC and Crohn’s colitis and the

“vitamin B complex” deficiencies are frequent in both diseases, we found no data about the

role of folate and the other members of the “vitamin B complex” in colorectal cancer

development in patients with Crohn’s disease affecting the colon. Future studies concerning

with the role of nutritional factors in colorectal neoplasia development should include

patients with Crohn’s colitis.

Clinical Syndromes Related to Deficiencies of the other Members of the

“Vitamin B Complex” (Except Folate and B12)

There are some rare cases in the literature reporting syndromes due to deficiencies of

water-soluble B vitamins in IBD patients, resembling beriberi (thiamine) [126], pellagra

(nicotinic acid) [127,128], or photophobia with dermatological changes (riboflavin) [129-

130].